NO975492L - Preparat for dignostisering av metabolsk syndrom samt sykdommer som omfatter syndromet - Google Patents

Preparat for dignostisering av metabolsk syndrom samt sykdommer som omfatter syndromet

Info

Publication number
NO975492L
NO975492L NO975492A NO975492A NO975492L NO 975492 L NO975492 L NO 975492L NO 975492 A NO975492 A NO 975492A NO 975492 A NO975492 A NO 975492A NO 975492 L NO975492 L NO 975492L
Authority
NO
Norway
Prior art keywords
syndrome
metabolic syndrome
dignostization
preparation
well
Prior art date
Application number
NO975492A
Other languages
English (en)
Other versions
NO975492D0 (no
NO319829B1 (no
Inventor
Per Maarin
Original Assignee
Cortendo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortendo Ab filed Critical Cortendo Ab
Publication of NO975492D0 publication Critical patent/NO975492D0/no
Publication of NO975492L publication Critical patent/NO975492L/no
Publication of NO319829B1 publication Critical patent/NO319829B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Combined Controls Of Internal Combustion Engines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO19975492A 1995-05-30 1997-11-28 Preparat for diagnostisering av metabolsk syndrom samt sykdommer som omfatter syndromet NO319829B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9501991A SE505391C2 (sv) 1995-05-30 1995-05-30 Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet
PCT/SE1996/000708 WO1996038179A1 (en) 1995-05-30 1996-05-30 Preparation for diagnostic of the metabolic syndrome and diseases including the syndrome

Publications (3)

Publication Number Publication Date
NO975492D0 NO975492D0 (no) 1997-11-28
NO975492L true NO975492L (no) 1998-01-27
NO319829B1 NO319829B1 (no) 2005-09-19

Family

ID=20398470

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19975492A NO319829B1 (no) 1995-05-30 1997-11-28 Preparat for diagnostisering av metabolsk syndrom samt sykdommer som omfatter syndromet

Country Status (16)

Country Link
US (1) US6410339B1 (no)
EP (1) EP0835138B1 (no)
JP (1) JPH11505850A (no)
CN (1) CN1078479C (no)
AT (1) ATE235258T1 (no)
AU (1) AU716671B2 (no)
BR (1) BR9608683A (no)
CA (1) CA2222215A1 (no)
DE (1) DE69626982T2 (no)
DK (1) DK0835138T3 (no)
ES (1) ES2189872T3 (no)
NO (1) NO319829B1 (no)
PT (1) PT835138E (no)
RU (1) RU2171471C2 (no)
SE (1) SE505391C2 (no)
WO (1) WO1996038179A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217505B2 (en) * 1998-02-26 2007-05-15 Cortendo Ab Method for determining whether condition is symptom of metabolic syndrome
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
US20090117660A1 (en) * 2005-04-30 2009-05-07 Oakville Hong Kong Co., Limited Devices and methods for sample collection and analysis
RU2520080C2 (ru) * 2006-10-06 2014-06-20 Нестек С.А. Композиции и мультипараметричекие способы анализа для измерения биологических медиаторов физиологического здоровья
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
RU2444298C1 (ru) * 2010-07-15 2012-03-10 Учреждение Российской академии медицинских наук Научный центр клинической и экспериментальной медицины Сибирского отделения РАМН (НЦКЭМ СО РАМН) Способ диагностики метаболического синдрома
CN105973881A (zh) * 2016-04-27 2016-09-28 樊福好 一种检测机体活度的溶液及检测方法

Also Published As

Publication number Publication date
DE69626982T2 (de) 2004-03-04
NO975492D0 (no) 1997-11-28
RU2171471C2 (ru) 2001-07-27
DE69626982D1 (de) 2003-04-30
EP0835138A1 (en) 1998-04-15
WO1996038179A1 (en) 1996-12-05
EP0835138B1 (en) 2003-03-26
AU716671B2 (en) 2000-03-02
ES2189872T3 (es) 2003-07-16
AU5917396A (en) 1996-12-18
CN1078479C (zh) 2002-01-30
NO319829B1 (no) 2005-09-19
ATE235258T1 (de) 2003-04-15
SE505391C2 (sv) 1997-08-18
CA2222215A1 (en) 1996-12-05
CN1185743A (zh) 1998-06-24
PT835138E (pt) 2003-08-29
JPH11505850A (ja) 1999-05-25
MX9709234A (es) 1998-10-31
US6410339B1 (en) 2002-06-25
SE9501991L (sv) 1996-12-01
DK0835138T3 (da) 2003-07-21
BR9608683A (pt) 1999-12-07
SE9501991D0 (sv) 1995-05-30

Similar Documents

Publication Publication Date Title
NO975492D0 (no) Preparat for dignostisering av metabolsk syndrom samt sykdommer som omfatter syndromet
Wright Jr et al. Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia
Tanner et al. Age‐related differences in lean mass, protein synthesis and skeletal muscle markers of proteolysis after bed rest and exercise rehabilitation
Yokoe et al. Intermittent hypoxia reverses the diurnal glucose rhythm and causes pancreatic β‐cell replication in mice
da Silva Alexandre et al. Prevalence and associated factors of sarcopenia among elderly in Brazil: findings from the SABE study
Spiegel et al. Impact of sleep debt on metabolic and endocrine function
Phillips et al. Alterations of protein turnover underlying disuse atrophy in human skeletal muscle
Grassi et al. Structural and functional alterations of subcutaneous small resistance arteries in severe human obesity
Rosenbloom et al. Chronic overtreatment with insulin in children and adolescents
Rosmond et al. Blood pressure in relation to obesity, insulin and the hypothalamic-pituitary-adrenal axis in Swedish men
Charloux et al. Sleep deprivation blunts the night time increase in aldosterone release in humans
Olsen et al. Relative influence of insulin resistance versus blood pressure on vascular changes in longstanding hypertension. ICARUS, a LIFE sub study
Liu et al. Asymmetry of habitual 24-hour intraocular pressure rhythm in glaucoma patients
WO2005117937A3 (en) Alpha-1- acid glycoprotein for the treatment of diabetes
RU97121292A (ru) Препарат для диагностики метаболического синдрома и заболеваний, включающих в себя данный синдром
Caisey et al. Influence of age and hormone replacement therapy on the functional properties of the lips
Lombardi et al. Periodic limb movements during sleep and blood pressure changes in sleep apnoea: Data from the European Sleep Apnoea Database
DE602004022968D1 (de) Ie behandlung mti insulinsensibilisatoren
Samuels et al. Salivary cortisol and daily events in nursing home residents
Harvey et al. Acute thermotherapy prevents impairments in cutaneous microvascular function induced by a high fat meal
Hezarkhani et al. Comparison of glycemic excursion in patients with new onset type 2 diabetes mellitus before and after treatment with repaglinide
Tarnow et al. Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy
Mulia et al. A16175 Barriers to Blood Pressure Control and Treatment Adherence in Hypertensive Management: An Observational Study in Resource-Poor Setting Hospital
Ahmadi et al. Psychological Stress and Type 2 Diabetes: A Review of the Bidirectional Link in the Onset and Progression of the Disease
Li et al. A15934 Daily sodium intake unfavorably affected the control of the office and home blood pressure in patients with resistant hypertension